

TRATTAMENTO FARMACOLOGICO DELLA BPCO STABILE

M. Cazzola, G. Di Maria

- 1) Birrell MA, Wong S, Hele DJ, McCluskie K, Hardaker E, Belvisi MG. **Steroid-resistant inflammation in a rat model of chronic obstructive pulmonary disease is associated with a lack of nuclear factor-kappaB pathway activation.** Am J Respir Crit Care Med 2005;172:74-84
- 2) Kiri VA, Pride NB, Soriano JB, Vestbo J. **Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias.** Am J Respir Crit Care Med 2005;172:460-464
- 3) van der Vaart H, Koeter GH, Postma DS, Kauffman HF, ten Hacken NH. **First study of infliximab treatment in patients with chronic obstructive pulmonary disease.** Am J Respir Crit Care Med 2005;172:465-469
- 4) Murakami S, Nagaya N, Itoh T, Iwase T, Fujisato T, Nishioka K, Hamada K, Kangawa K, Kimura H. **Adrenomedullin regenerates alveoli and vasculature in elastase-induced pulmonary emphysema in mice.** Am J Respir Crit Care Med 2005;172:581-589
- 5) Martorana PA, Beume R, Lucattelli M, Wollin L, Lungarella G. **Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke.** Am J Respir Crit Care Med 2005;172:848-853
- 6) Lee JH, Lee DS, Kim EK, Choe KH, Oh YM, Shim TS, Kim SE, Lee YS, and Lee SD **Simvastatin Inhibits Cigarette Smoking–induced Emphysema and Pulmonary Hypertension in Rat Lungs** Am. J. Respir. Crit. Care Med. 2005; 172: 987-993.
- 7) Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery PK. **Anti-inflammatory effects of salmeterol/ fluticasone propionate in chronic obstructive lung disease.** In press
- 8) Decramer M, Rutten-van Molken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CP, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A. **Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.** Lancet 2005;365:1552-60
- 9) Barnes PJ, Ito K, Adcock IM. **Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase.** Lancet 2004;363:731-3
- 10) Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, Barnes PJ. **Decreased histone deacetylase activity in chronic obstructive pulmonary disease.** N Engl J Med 2005;352:1967-76

- 11) Barnes PJ, Stockley RA. **COPD: current therapeutic interventions and future approaches.** Eur Respir J 2005;25:1084-106.
- 12) Barnes PJ, Adcock IM, Ito K. **Histone acetylation and deacetylation: importance in inflammatory lung diseases.** Eur Respir J 2005;25:552-63
- 13) Liao JK. **Clinical implications for statin pleiotropy.** Curr Opin Lipidol 2005;16:624-629
- 14) Lee SD, Lee JH, Kim EK, Choi KH, Oh YM, Shim TS. **Effects of simvastatin on cigarette smoking-induced structural and functional changes in rat lungs.** Chest 2005;128:574S
- 15) Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciruba FC, Richter K, Kesten S, O'Donnell D. **Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD.** Chest 2005;128:1168-78
- 16) O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H. **Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.** Eur Respir J 2004;23:832-40
- 17) Donohue JF. **Therapeutic responses in asthma and COPD. Bronchodilators.** Chest 2004;126:125S-137S; discussion 159S-161S
- 18) Pepin V, Saey D, Whittom F, Leblanc P, Maltais F. **Walking versus Cycling: Sensitivity to Bronchodilation in Chronic Obstructive Pulmonary Disease.** Am J Respir Crit Care Med 2005;172:1517-22
- 19) Higenbottam T. **Pulmonary hypertension and chronic obstructive pulmonary disease: a case for treatment.** Proc Am Thorac Soc 2005;2:12-9
- 20) Wright JL, Levy RD, Churg A. **Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment.** Thorax 2005;60:605-9
- 21) Celli BR, MacNee W. **Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.** Eur Respir J 2004;23:932-46
- 22) Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. **Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.** Eur Respir J 2003;21:74-81
- 23) Calverley PM, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. **Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.** Lancet 2003;361:449-56

- 24) Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. **Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease.** Eur Respir J 2003;22:912-9
- 25) Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA, Jr., Korducki L, Cassino C, Kesten S. **Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.** Ann Intern Med 2005;143:317-26
- 26) van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, Mueller A, Cornelissen PJ. **Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.** Eur Respir J 2005;26:214-22
- 27) Jones PW, Willits LR, Burge PS, Calverley PM. **Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations.** Eur Respir J 2003;21:68-73
- 28) Sin DD, Wu L, Anderson JA, Anthonisen NR, Buist AS, Burge PS, Calverley PM, Connett JE, Lindmark B, Pauwels RA, Postma DS, Soriano JB, Szafranski W, Vestbo J. **Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease.** Thorax 2005;60:992-7
- 29) Lipworth BJ. **Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.** Lancet 2005;365:167-75
- 30) Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroeker D, Bethke TD. **Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.** Lancet 2005;366:563-71
- 31) Fitzgerald JM, Boulet LP, Follows RM. **The CONCEPT trial: a 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.** Clin Ther. 2005; 27 (4): 393-406
- 32) **Global Initiative for Chronic Obstructive Lung Disease. Update 1 July 2005.** A collaborative project of the National Health L, and Blood Institute, NIH and the World Health Organisation., ed. www.goldcopd.com: National Institutes of Health, National Heart Lung and Blood Institute, Bethesda, Md, 2005.
- 33) van noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, Mueller A, Cornelissen PJG. **Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.** Eur Respir J 2005; 26:214-222
- 34) Buhl Roland and Farmer SG.. **Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease.** Proc Am Thorac Soc Vol 2. pp 83–93, 2005

